# US 2015/0105746 A1 · Long term drug delivery devices with polyurethane-based polymers and their manufacture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105746 A1
- Document ID: US20150105746A1
- Status: Published application
- Kind: A1
- Application number: 14/306,954
- Filed: 2014-06-17
- Published: 2015-04-16
- Earliest claimed: 2008-09-30
- Assignees: Endo Pharmaceuticals Solutions Inc.
- Applicants: Endo Pharmaceuticals Solutions Inc.
- Inventors: Petr Kuzma; Harry Quandt
- Web page: https://patentgrep.com/patent/US20150105746A1

## CPC

- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/4168: having a nitrogen attached in position 2, e.g. clonidine
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 38/09: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61M 37/00: Other apparatus for introducing media into the body (for reproduction or fertilisation A61B17/425; apparatus for iontophoresis or cataphoresis A61N1/30); Percutany, i.e. introducing medicines into the body by diffusion through the skin (salt baths A61H33/04)
- Y10T 29/49826: Assembling or joining
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.

## Claims

### Claim 1

An implantable drug delivery device, comprising a polyurethane-based polymer having polyether-based polyol segments represented by the formula —[O—(CH2)n]x—O—, said polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of solid formulation comprising an active agent and one or more pharmaceutically acceptable carriers, such that the release of the active agent at a substantially zero order rate in vitro by diffusion through the polyurethane-based polymer generally increases as the equilibrium water content (% EWC) of the polymer increases, wherein the active agent is histrelin, risperidone, dexamethasone, naltrexone, metolazone, clonidine, or selegiline.

### Claim 2 (depends on 1)

The drug delivery device of claim 1, wherein the active agent is histrelin.

### Claim 3 (depends on 1)

The drug delivery device of claim 1, wherein the active agent is risperidone.

### Claim 4 (depends on 1)

The drug delivery device of claim 1, wherein the active agent is dexamethasone.

### Claim 5 (depends on 1)

The drug delivery device of claim 1, wherein the active agent is naltrexone.

### Claim 6 (depends on 1)

The drug delivery device of claim 1, wherein the active agent is metolazone.

### Claim 7 (depends on 1)

The drug delivery device of claim 1, wherein the active agent is clonidine.

### Claim 8 (depends on 1)

The drug delivery device of claim 1, wherein the active agent is selegiline.

### Claim 9 (depends on 1)

The drug delivery device of claim 1, wherein the polyurethane-based polymer has a % EWC of between about 5%-43%.

### Claim 10 (depends on 1)

The drug delivery device of claim 1, wherein the one or more pharmaceutically acceptable carriers is selected from the group consisting of croscarmellose, stearic acid, and a combination thereof.

### Claim 11 (depends on 10)

The drug delivery device of claim 10, wherein the one or more pharmaceutically acceptable carriers are croscarmellose and stearic acid.

### Claim 12 (depends on 11)

The drug delivery device of claim 11, wherein the croscarmellose comprises 10% of the solid drug formulation, and stearic acid comprises 2% of the solid drug formulation.

### Claim 13 (depends on 1)

The drug delivery device of claim 1, wherein the reservoir has a wall thickness of 0.2 mm.

### Claim 14

A method of delivering an active agent to a subject, comprising implanting an implantable device into the subject, wherein the implantable device comprises a polyurethane-based polymer having polyether-based polyol segments represented by the formula —[O—(CH2)n]x—O—, said polyurethane-based polymer configured to provide a cylindrically shaped reservoir, wherein the reservoir is sealed after being charged with an effective amount of solid formulation comprising an active agent and one or more pharmaceutically acceptable carriers, such that the release of the active agent at a substantially zero order rate in vitro by diffusion through the polyurethane-based polymer generally increases as the equilibrium water content (% EWC) of the polymer increases, wherein the active agent is histrelin, risperidone, dexamethasone, naltrexone, metolazone, clonidine, or selegiline.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The method of claim 14, wherein the active agent is risperidone.

### Claim at position 17

17-42. (canceled)
